## **Prior Authorization Form**



**Note:** Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information		Presc	riber Information	
Patient Name:		Prescriber Name:		
Health Plan Name:		Prescriber Address:		
Patient Insurance Id:				
Patient Date of Birth:		Prescriber Phone:	( )	
Patient Phone:		Prescriber Fax:	( )	
-		Prescriber Specialty:	<u> </u>	
		Prescriber DEA:		
		Prescriber NPI:		
Medica	tion & Med	dical Information		
Requested Drug(s) & Strength(s):			00 mg tablet [ ] Cibinqo 50 mg tablet	
Requested Daily Quantity Limit – Amount:				
Requested Daily Quantity Limit – Days:				
Expected Length of Therapy:				
Directions:				
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):				
List drugs used previously to treat the same condition:				
Additional clinical information or history. Please include any relevant test results and/or medical record notes:				
Overskierweins				
Questionnaire  Q1: I, as the provider or designated representative of the provider, certify and attest that the information provided is complete and accurate and that, upon request, I shall provide any information to RxAdvance that RxAdvance determines is reasonably necessary to verify my responses. (Check only one that apply)  [] Yes				
[] No	2/2			
Q2: Is the member currently treated with this medication? (Check only one that apply)				
[] Yes (please list start date of therapy (month/d (*Required)	ay/year))			
[] No				
Q3: What is the member's diagnosis? (Check only one	that apply)			

## **Prior Authorization Form**



[ ] Moderate to severe atopic dermatitis
[] Other (please specify the member's diagnosis and provide clinical rationale for the request)(*Required)
Q4: Does the member have documentation supporting positive clinical response to therapymas evidenced by at least one of the following: reduction in body surface area (BSA) involvement from baseline, or reduction in SCORAD index value from baseline? (Check only one that apply)
[ ] Yes (please provide documentation(s) supporting the positive response of the therapy)(*Required)
[ ] No (please provide medical justification for continuation of therapy)(*Required)
Q5: Is the prescribed medication used in combination with other janus kinase (JAK) inhibitors, biologic immunomodulators, or other immunosuppressants (eg, azathioprine, cyclosporine)? (Check only one that apply)
[ ] Yes (please provide medical justification for continuation of therapy)(*Required)
[] No
Q6: What is the member's diagnosis? (Check only one that apply)
[ ] Moderate to severe atopic dermatitis
[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request)(*Required)
Q7: Does member's diagnosis supported by one of the following criteria? (Check only one that apply)
[ ] Involvement of at least 10% body surface area (BSA)
[] SCORing Atopic Dermatitis (SCORAD) index value of at least 25
[ ] None of the above (please provide medical justification for the request)(*Required)
Q8: Has the member had an inadequate response, contraindication(s) or have intolerance to at least 14 days trial of medium or higher potency topical corticosteroid? (Check only one that apply)
[ ] Yes (please specify drug name, corresponding contraindication(s) or intolerance experienced and the start and end date(s of therapy (month/year))(*Required)
[] No
Q9: Has the member had an inadequate response, contraindication(s) or have intolerance to at least 30 days trial of pimecrolinucream? (Check only one that apply)
[ ] Yes (please specify corresponding contraindication(s) or intolerance experienced and the start and end date(s) of therapy (month/year))(*Required)
[] No
Q10: Has the member had an inadequate response, contraindication(s) or have intolerance to at least 30 days trial of tacrolimus ointment? (Check only one that apply)
[] Yes (please specify corresponding contraindication(s) or intolerance experienced and the start and end date(s) of therapy (month/year))(*Required)
[] No

## Prior Authorization Form



(crisaborole) ointment? (Check only one that apply)	tolerance to at least 30 day trial of Eucrisa
[ ] Yes (please specify corresponding contraindication(s) or intolerance experi (month/year))(*R	
[ ] No (please provide clinical rationale for the request)(*Required)	
Q12: Has the member had an inadequate response to a minimum 12-week supply treatment of atopic dermatitis (examples include, but are not limited to, Adbry [track only one that apply)	
[] Yes (please specify drug name(s) and the start and end date(s) of therapy ( (*Required)	month/year))
[] No	
Q13: Has the member had contraindication, intolerance, or treatment is inadvisab atopic dermatitis therapies: Adbry (tralokinumab-ldrm) and Dupixent (dupilumab)	
[ ] Yes (please specify corresponding contraindication(s), intolerance experien start and end date(s) of therapy (month/year))	
[ ] No (please provide clinical rationale for the request)(*Required)	
Q14: Is the prescribed medication used in combination with other Janus kinase (JA other immunosuppressants (eg, azathioprine, cyclosporine)? (Check only one that	,
[ ] Yes (please provide clinical rationale for the request)(*Required)	
[] No	
Q15: Is the member at least 18 years old? (Check only one that apply)	
[] Yes	
[] No (please provide member's age and clinical rationale for the request)(*Required)	
Q16: Is the requested medication prescribed by or in consultation with a dermatol that apply)	ogist or allergist/immunologist? (Check only one
[ ] Yes (please specify prescriber(s) specialty)	(*Required)
[ ] No (please provide clinical rationale for the request)(*Required)	
<u>Attestation:</u> I attest the information provided is true and accurate to the best of my knowle Medical Group or its designated representatives may perform a routine audit and request to accuracy of the information reported on this form.	
Signature of Prescriber or Authorized Representative:	Date:
Print Authorized Representative Name:	